Shares of Mednax Inc. (NYSE:MD) have been assigned a consensus recommendation of “Buy” from the eleven analysts that are covering the stock. Five investment analysts have rated the stock with a hold recommendation and six have given a buy recommendation to the company. The average 1 year target price among brokerages that have issued ratings on the stock in the last year is $74.38.
Several equities research analysts recently issued reports on MD shares. Zacks Investment Research downgraded Mednax from a “hold” rating to a “sell” rating in a report on Wednesday, October 19th. Mizuho reiterated a “buy” rating and set a $79.00 price target on shares of Mednax in a report on Tuesday, September 20th. Jefferies Group decreased their price target on Mednax from $80.00 to $75.00 and set a “buy” rating for the company in a report on Friday, August 26th. JPMorgan Chase & Co. decreased their price target on Mednax from $85.00 to $80.00 and set an “overweight” rating for the company in a report on Friday, July 29th. Finally, Raymond James Financial Inc. downgraded Mednax from an “outperform” rating to a “market perform” rating in a report on Thursday.
In other news, Director Md Pascal J. Goldschmidt sold 1,500 shares of the company’s stock in a transaction on Wednesday, September 14th. The stock was sold at an average price of $65.01, for a total transaction of $97,515.00. Following the transaction, the director now owns 12,755 shares of the company’s stock, valued at approximately $829,202.55. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 2.40% of the company’s stock.
Hedge funds and other institutional investors have recently modified their holdings of the stock. OLD Mutual Customised Solutions Proprietary Ltd. purchased a new position in shares of Mednax during the second quarter worth approximately $101,000. Parkside Financial Bank & Trust boosted its position in shares of Mednax by 30.1% in the second quarter. Parkside Financial Bank & Trust now owns 1,406 shares of the company’s stock worth $102,000 after buying an additional 325 shares in the last quarter. Mizuho Asset Management Co. Ltd. purchased a new position in shares of Mednax during the second quarter worth approximately $107,000. Pacer Advisors Inc. boosted its position in shares of Mednax by 9.5% in the second quarter. Pacer Advisors Inc. now owns 1,760 shares of the company’s stock worth $127,000 after buying an additional 152 shares in the last quarter. Finally, First Quadrant L P CA purchased a new position in shares of Mednax during the second quarter worth approximately $130,000. 97.79% of the stock is currently owned by hedge funds and other institutional investors.
Mednax (NYSE:MD) opened at 60.89 on Tuesday. The company has a market cap of $5.61 billion, a PE ratio of 16.99 and a beta of 0.54. The firm’s 50-day moving average price is $65.63 and its 200 day moving average price is $68.41. Mednax has a 52-week low of $59.36 and a 52-week high of $76.96.
Mednax (NYSE:MD) last announced its quarterly earnings results on Thursday, October 27th. The company reported $1.09 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $1.11 by $0.02. Mednax had a return on equity of 14.47% and a net margin of 10.97%. The company had revenue of $828 million for the quarter, compared to the consensus estimate of $821.18 million. During the same quarter last year, the company posted $1.10 EPS. The company’s quarterly revenue was up 14.6% compared to the same quarter last year. On average, equities analysts predict that Mednax will post $4.11 EPS for the current fiscal year.